Penumbra (NYSE:PEN) Cut to “Hold” at Wells Fargo & Company

Penumbra (NYSE:PEN) was downgraded by investment analysts at Wells Fargo & Company from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

PEN has been the topic of a number of other research reports. Bank of America upped their price objective on Penumbra from $320.00 to $370.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $355.00 price target on shares of Penumbra in a research report on Wednesday, December 17th. Citigroup downgraded shares of Penumbra from a “buy” rating to a “neutral” rating in a research report on Thursday. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a research note on Monday, December 29th. Finally, Evercore ISI reiterated an “outperform” rating and issued a $340.00 target price on shares of Penumbra in a research note on Monday, January 5th. Ten equities research analysts have rated the stock with a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $354.38.

Penumbra Stock Up 11.8%

Shares of Penumbra stock opened at $350.53 on Thursday. Penumbra has a 52-week low of $221.26 and a 52-week high of $352.15. The business’s 50 day simple moving average is $301.84 and its 200 day simple moving average is $268.86. The firm has a market cap of $13.73 billion, a PE ratio of 83.86, a P/E/G ratio of 1.92 and a beta of 0.71. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.18 and a current ratio of 6.73.

Penumbra (NYSE:PEN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.07. Penumbra had a net margin of 12.30% and a return on equity of 11.35%. The firm had revenue of $354.69 million for the quarter, compared to analyst estimates of $340.77 million. During the same period in the previous year, the business earned $0.85 EPS. The company’s revenue was up 17.8% compared to the same quarter last year. On average, analysts predict that Penumbra will post 3.67 earnings per share for the current fiscal year.

Insider Transactions at Penumbra

In other Penumbra news, Director Arani Bose sold 15,000 shares of the stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $308.82, for a total transaction of $4,632,300.00. Following the transaction, the director owned 258,462 shares in the company, valued at $79,818,234.84. This trade represents a 5.49% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Harpreet Grewal sold 186 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $312.64, for a total value of $58,151.04. Following the completion of the sale, the director owned 8,230 shares of the company’s stock, valued at approximately $2,573,027.20. This trade represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 34,144 shares of company stock valued at $10,260,127. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Penumbra

Hedge funds and other institutional investors have recently made changes to their positions in the company. Royal Bank of Canada grew its stake in Penumbra by 35.8% during the first quarter. Royal Bank of Canada now owns 19,332 shares of the company’s stock valued at $5,169,000 after acquiring an additional 5,092 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Penumbra by 53.8% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 4,999 shares of the company’s stock valued at $1,255,000 after purchasing an additional 1,748 shares during the last quarter. Diversified Trust Co grew its position in shares of Penumbra by 33.3% during the second quarter. Diversified Trust Co now owns 8,365 shares of the company’s stock valued at $2,147,000 after purchasing an additional 2,089 shares in the last quarter. Farther Finance Advisors LLC increased its holdings in shares of Penumbra by 408.3% in the second quarter. Farther Finance Advisors LLC now owns 2,262 shares of the company’s stock worth $580,000 after purchasing an additional 1,817 shares during the last quarter. Finally, Park Avenue Securities LLC bought a new stake in shares of Penumbra in the second quarter worth about $408,000. 88.88% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Penumbra

Here are the key news stories impacting Penumbra this week:

• Positive Sentiment: Boston Scientific has agreed to acquire Penumbra in a cash-and-stock transaction that values Penumbra at about $14.5 billion, providing a significant premium to the prior market price and driving the stock higher. Read More.
• Positive Sentiment: News coverage and deal write-ups highlight strategic benefits for Boston Scientific (expanded thrombectomy and neurovascular capabilities), which supports the rationale for the acquisition premium and underpins investor enthusiasm for PEN. Read More.
• Neutral Sentiment: Penumbra issued a preliminary fourth-quarter and full-year 2025 results update and provided revenue guidance that was roughly in line with expectations — this supports deal valuation but will be audited and finalized. Read More.
• Neutral Sentiment: Analyst commentary and earnings-estimate revisions have turned more positive following the acquisition news, which can sustain near-term upside as markets reprice consensus estimates. Read More.
• Negative Sentiment: Several shareholder-law firms have announced investigations into whether the sale price and process were fair to Penumbra shareholders; litigation or regulatory scrutiny could delay closing or lead to renegotiation. Read More.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.